Marina Neystat, MD
Neurology · Forest Hills, NYNPI 1124013990
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.8% of the total across 1,391 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 60 manufacturers, the largest accounting for just 15.5% — the pattern of someone who eats at a lot of different presentations.
Across 1,391 payments — averaging $19.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$4K
- Amgen$2K
- UCB, Inc.$1K
- SK Life Science, Inc.$1K
- Biogen$1K
- Genentech USA, Inc.$1K
- plus $16K from 54 others
What the payments were for
- Food & beverage$27,159100%
- Education$550%
- Gifts$00%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- AIMOVIG$311
- BOTOX$138
- EMGALITY$111
- GENERAL DBS$103
How this compares
$27,214 in reported general payments places this provider in the 85th percentile of 1,623 neurology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| NortheraDroxidopa | 70 | $1,123,077 |
| Nurtec OdtRimegepant Sulfate | 642 | $830,341 |
| UbrelvyUbrogepant | 279 | $344,245 |
| HorizantGabapentin Enacarbil | 554 | $337,018 |
| QuliptaAtogepant | 296 | $315,553 |
| IngrezzaValbenazine Tosylate | 36 | $311,258 |
| Diclofenac Sodium | 532 | $288,481 |
| Dihydroergotamine Mesylate | 227 | $279,541 |
| RytaryCarbidopa/Levodopa | 265 | $263,293 |
| NuedextaDextromethorphan Hbr/Quinidine | 178 | $253,053 |
| NeuproRotigotine | 268 | $227,724 |
| NamzaricMemantine Hcl/Donepezil Hcl | 328 | $206,705 |
| GraliseGabapentin | 353 | $199,534 |
| TrintellixVortioxetine Hydrobromide | 285 | $147,225 |
| Emgality PenGalcanezumab-Gnlm | 206 | $144,680 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lundbeck LLCNorthera, Vyepti | $1,161 | $1,183,54883 claims |
| AbbVieUbrelvy, Qulipta, Namzaric, Botox | $4,228 | $973,960987 claims |
| PfizerNurtec Odt | $522 | $830,341642 claims |
| Arbor Pharmaceuticals, Inc.Horizant | $559 | $337,018554 claims |
| UCB, Inc.Neupro, Briviact | $1,428 | $321,819333 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $548 | $311,25836 claims |
| Amneal Pharmaceuticals LLCRytary | $467 | $263,293265 claims |
| Avanir Pharmaceuticals, Inc.Nuedexta | $175 | $253,053178 claims |
| BiogenTecfidera, Vumerity | $1,254 | $207,39325 claims |
| Almatica Pharma LLCGralise | $170 | $199,534353 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $741 | $147,225285 claims |
| Scilex Pharmaceuticals Inc.Ztlido | $713 | $129,831353 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,623 neurology providers in New York.
Other neurology in Forest Hills
- Idan SharonBrooklyn$2.1M
- Allan PerelStaten Island$1.7M
- Nicolas SaikaliAmherst$1.5M
- David KreitzmanCommack$1.5M
- Charles ArgoffAlbany$1.2M
- Stephen KriegerNew York$1.1M
- Robert FeketeHawthorne$1M
- Jennifer McVigeAmherst$982K
- Warren SpinnerPort Jefferson Station$791K
- Richard LiptonBronx$753K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.